Greg Fulcher

16.7k total citations · 4 hit papers
65 papers, 9.5k citations indexed

About

Greg Fulcher is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Greg Fulcher has authored 65 papers receiving a total of 9.5k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Endocrinology, Diabetes and Metabolism, 24 papers in Surgery and 9 papers in Molecular Biology. Recurrent topics in Greg Fulcher's work include Diabetes Treatment and Management (36 papers), Diabetes Management and Research (26 papers) and Pancreatic function and diabetes (19 papers). Greg Fulcher is often cited by papers focused on Diabetes Treatment and Management (36 papers), Diabetes Management and Research (26 papers) and Pancreatic function and diabetes (19 papers). Greg Fulcher collaborates with scholars based in Australia, United States and Netherlands. Greg Fulcher's co-authors include Bruce Neal, Dick de Zeeuw, Kenneth W. Mahaffey, Vlado Perkovic, David R. Matthews, Wayne Shaw, Mehul Desai, Ngozi Erondu, Gordon Law and Terrance D. Barrett and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Greg Fulcher

63 papers receiving 9.2k citations

Hit Papers

Canagliflozin and Cardiovascular and Renal Events in Type... 2017 2026 2020 2023 2017 2018 2017 2018 1000 2.0k 3.0k 4.0k 5.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
    2017 5.4k citations Bruce Neal, Vlado Perkovic et al. New England Journal of Medicine profile →
  2. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
    2018 468 citations Vlado Perkovic, Dick de Zeeuw et al. profile →
  3. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events
    2017 375 citations Kenneth W. Mahaffey, Bruce Neal et al. Circulation profile →
  4. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus
    2018 368 citations Karin Rådholm, Gemma A. Figtree et al. Circulation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Greg Fulcher Australia 32 7.8k 3.4k 2.9k 1.8k 1.1k 65 9.5k
Avivit Cahn Israel 29 7.7k 1.0× 3.0k 0.9× 3.1k 1.1× 2.0k 1.1× 824 0.7× 113 9.3k
Ingrid Gause‐Nilsson Sweden 31 6.1k 0.8× 2.5k 0.7× 2.7k 0.9× 1.7k 0.9× 648 0.6× 71 7.6k
B Charbonnel France 46 7.1k 0.9× 2.8k 0.8× 3.3k 1.1× 1.2k 0.7× 470 0.4× 240 9.7k
Michael G. Silverman United States 22 4.5k 0.6× 2.6k 0.8× 1.9k 0.6× 2.0k 1.1× 534 0.5× 44 6.8k
C. David Sjöström Sweden 44 6.2k 0.8× 5.6k 1.7× 2.2k 0.7× 1.6k 0.9× 2.0k 1.8× 116 12.1k
Gary Meininger United States 40 7.3k 0.9× 3.8k 1.1× 3.0k 1.0× 450 0.2× 639 0.6× 80 8.3k
Paola Fioretto Italy 53 4.1k 0.5× 2.0k 0.6× 1.9k 0.6× 1.9k 1.1× 4.5k 4.1× 201 10.2k
Gilbert H. Daniels United States 42 9.8k 1.3× 3.2k 0.9× 2.8k 1.0× 1.4k 0.8× 228 0.2× 102 12.3k
Giancarlo Viberti United Kingdom 62 6.6k 0.8× 2.1k 0.6× 3.7k 1.3× 3.8k 2.0× 4.0k 3.6× 190 13.7k
Anna Solini Italy 48 2.6k 0.3× 1.3k 0.4× 1.9k 0.6× 1.5k 0.8× 1.1k 1.0× 233 7.4k

Countries citing papers authored by Greg Fulcher

Since Specialization
Citations

This map shows the geographic impact of Greg Fulcher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Greg Fulcher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Greg Fulcher more than expected).

Fields of papers citing papers by Greg Fulcher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Greg Fulcher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Greg Fulcher. The network helps show where Greg Fulcher may publish in the future.

Co-authorship network of co-authors of Greg Fulcher

This figure shows the co-authorship network connecting the top 25 collaborators of Greg Fulcher. A scholar is included among the top collaborators of Greg Fulcher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Greg Fulcher. Greg Fulcher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Neuen, Brendon L., Toshiaki Ohkuma, Bruce Neal, et al.. (2020). Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. American Journal of Kidney Diseases. 77(1). 23–34.e1. 50 indexed citations
3.
Zhou, Zien, Meg Jardine, Vlado Perkovic, et al.. (2019). Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program. Diabetologia. 62(10). 1854–1867. 59 indexed citations
4.
Neuen, Brendon L., Toshiaki Ohkuma, Bruce Neal, et al.. (2019). Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. Journal of the American Society of Nephrology. 30(11). 2229–2242. 101 indexed citations
5.
Zhou, Zien, Richard I. Lindley, Karin Rådholm, et al.. (2018). Canagliflozin and Stroke in Type 2 Diabetes Mellitus. Stroke. 50(2). 396–404. 53 indexed citations
6.
Lo, Clement, Edward Zimbudzi, Helena Teede, et al.. (2018). Models of care for co‐morbid diabetes and chronic kidney disease. Nephrology. 23(8). 711–717. 20 indexed citations
7.
Neuen, Brendon L., Toshiaki Ohkuma, Bruce Neal, et al.. (2018). Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Circulation. 138(15). 1537–1550. 188 indexed citations
8.
Rådholm, Karin, Gemma A. Figtree, Vlado Perkovic, et al.. (2018). Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus. Circulation. 138(5). 458–468. 368 indexed citations breakdown →
9.
Jenkins, Alicia J., Gary Kilov, Emma Scott, et al.. (2018). Type 1 Diabetes Glucose Control related Home-Based Testing: A Mini-Review of Tools and Patient Knowledge and Implementation. 2(1). 55–62. 1 indexed citations
10.
Mahaffey, Kenneth W., Bruce Neal, Vlado Perkovic, et al.. (2017). Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events. Circulation. 137(4). 323–334. 375 indexed citations breakdown →
11.
Neal, Bruce, Vlado Perkovic, Kenneth W. Mahaffey, et al.. (2017). Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine. 377(7). 644–657. 5379 indexed citations breakdown →
12.
Lo, Clement, Dragan Ilić, Helena Teede, et al.. (2016). Primary and tertiary health professionals’ views on the health-care of patients with co-morbid diabetes and chronic kidney disease – a qualitative study. BMC Nephrology. 17(1). 50–50. 25 indexed citations
13.
Shaw, Jonathan E., Naresh M. Punjabi, Matthew T. Naughton, et al.. (2016). The Effect of Treatment of Obstructive Sleep Apnea on Glycemic Control in Type 2 Diabetes. American Journal of Respiratory and Critical Care Medicine. 194(4). 486–492. 100 indexed citations
14.
Wu, Ted, Michelle Downie, Manish Khanolkar, et al.. (2015). Practical Guidance on the Use of Premix Insulin Analogs in Initiating, Intensifying, or Switching Insulin Regimens in Type 2 Diabetes. Diabetes Therapy. 6(3). 273–287. 23 indexed citations
15.
16.
Zinman, Bernard, Greg Fulcher, Nihal Thomas, et al.. (2010). Insulin degludec, a new generation ultra-long acting insulin, used once daily or 3-times weekly in people with type 2 diabetes: comparison to insulin glargine. Diabetes. 59. 5 indexed citations
17.
Tacon, Lyndal, et al.. (2008). Drug-Induced Thyroiditis and Papillary Carcinoma in a Minocycline-Pigmented Black Thyroid Gland. Thyroid. 18(7). 795–797. 10 indexed citations
18.
Scott, Russell, Richard O’Brien, Greg Fulcher, et al.. (2008). Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome. Diabetes Care. 32(3). 493–498. 397 indexed citations
19.
Thomas, Merlin C., Richard J. MacIsaac, Con Tsalamandris, et al.. (2004). The burden of anaemia in type 2 diabetes and the role of nephropathy: a cross-sectional audit. Nephrology Dialysis Transplantation. 19(7). 1792–1797. 99 indexed citations
20.
McElduff, Aidan, Borys Shuter, Linda Davies, et al.. (1997). Measuring Renal Function in Patients With Diabetes Mellitus. Journal of Diabetes and its Complications. 11(4). 225–229. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Avivit Cahn Breakdown of academic impact, for papers by Ingrid Gause‐Nilsson Breakdown of academic impact, for papers by B Charbonnel Breakdown of academic impact, for papers by Michael G. Silverman Breakdown of academic impact, for papers by C. David Sjöström Breakdown of academic impact, for papers by Gary Meininger Breakdown of academic impact, for papers by Paola Fioretto Breakdown of academic impact, for papers by Gilbert H. Daniels Breakdown of academic impact, for papers by Giancarlo Viberti Breakdown of academic impact, for papers by Anna Solini
Rankless by CCL
2026